ClinicalTrials.gg
CompletedNCT00778622Updated Aug 23, 2013Results posted

Body Weight Effects on Glucophage's Efficacy in Chinese Diagnosed T2DM Patients

A Phase 4 interventional study of Metformin XR in Type 2 Diabetes Mellitus, sponsored by Bristol-Myers Squibb. Completed at 14 sites in China. Open to participants aged 17 Years to 79 Years. Per ClinicalTrials.gov, last updated 2013-08-23.

Sponsored by Bristol-Myers Squibb · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
371
Allocation
Non-randomized
Ages
17 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.

Enrollment
61st of 287
371 · median 100
Started
2009
with 13 others
Phase 4
98 of 293
6 open now
Registered
76th of 293
by date

Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 61st largest by enrollment of the 287 interventional ones that give a count, is one of 14 that started in 2009, is one of 98 in phase 4, and was the 76th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About metformin

Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 17 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies testing metformin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the effect of the baseline body mass index (BMI) on the response to Glucophage XR monotherapy in glycemic control in Chinese patients with newly diagnosed type 2 diabetes

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
17 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed Written
  • Age≥ 17 and \<80 years,
  • Newly diagnosed T2DM (defined as T2DM diagnosed within 6 months prior to enrollment)
  • Oral antidiabetic agents naïve (defined as without receiving any anti-diabetic medication therapy before, or having received anti-diabetic medication ≤ 14 days but not received any antidiabetic medication within the last 1 month prior to enrollment)
  • ≥ 7.0% and ≤10.0%

Exclusion criteria

Exclusion Criteria:

  • Women of child bearing potential
  • (BMI)≥35 Kg/m2 or BMI \<18.5 Kg/m2
  • (HbA1c)>10.0% or \<7.0%
  • Active liver disease and/or significant abnormal liver function
  • Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma
  • Congestive heart failure defined as (NYHA) class III or IV and /or ≤40%
  • Significant cardiovascular history with the past 6 months
  • Severe retinopathy, persistent uncontrolled hypertension (SBP≥180mmHg, or DBP≥105mmHg)
  • Severe chronic gastrointestinal disease
  • History of alcohol abuse or illegal drug abuse within the past 12 months
  • Diagnosed anemia
  • Creatine kinase ≥3 X
  • Serum creatinine ≥1.5 mg/dL(133μmol/L) [males], ≥1.4 mg/dL(124 μmol/L)[females]
  • Alanine amino transferase () and/or aspartate amino transferase (AST)> 1.5 X ULN and/or total > 2 X ULN
  • \<12g/dL [males], \<11g/dL [females]
  • Allergies and Adverse Drug Reactions
  • Prohibited Treatments and/or Therapies
  • Prisoners or subjects who are involuntarily incarcerated
  • Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness
  • Subjects decline to participate
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
371 participants (actual)

Study arms

  • Experimental
    A1

    Normal Weight by Body Weight Index

    Drug: Metformin XR

  • Experimental
    A2

    Overweight by Body Weight Index

    Drug: Metformin XR

  • Experimental
    A3

    Obese by Body Weight Index

    Drug: Metformin XR

Interventions

  • Tablets, Oral, 500mg tid, 1500 mg/day, 16 weeks

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline at Week 16 (95% Confidence Interval) in Glycosated Hemoglobin A1c (HbA1c) (Last Observation Carried Forward) - Full Analysis Set (FAS)

    Baseline for HbA1c is defined as that value obtained at screening visit. HbA1c was measured as a percent (%) of hemoglobin; normal range was 4.7 to 6.4% and values were obtained through a central laboratory. The Last Observation Carried Forward (LOCF) data set includes data recorded at a given visit or, if no observation is recorded at that visit, data carried forward from the previous visit.

    Time frame: Baseline to Week 16

Secondary outcomes

  1. Mean Change From Baseline at Week 16 (95% Confidence Interval) of Fasting Plasma Glucose (FPG) - Full Analysis Set

    Baseline was defined as the value obtained at the screening visit. FPG was measured in millimoles/Liter (mmol/L) and obtained through local laboratories.

    Time frame: Baseline to Week 16

  2. Mean Change From Baseline at Week 16 (95% Confidence Interval) in Fasting Total Cholesterol (TC) - Full Analysis Set

    For fasting total cholesterol (TC), baseline is defined as Day 1 (first day of treatment). Total cholesterol was measured in millimoles per liter (mmol/L) and obtained through local laboratories.

    Time frame: Baseline to Week 16

  3. Mean Change From Baseline at Week 16 (95% Confidence Interval) in Fasting Low-density Lipoprotein Cholesterol (LDL-C) - Full Analysis Set

    Baseline was defined as values obtained on Day 1. Low-density lipoprotein cholesterol (LDL-C) was measured in millimoles per liter (mmol/L) and obtained through local laboratories.

    Time frame: Baseline to Week 16

  4. Mean Change From Baseline at Week 16 (95% Confidence Interval) in Fasting High-density Lipoprotein Cholesterol (HDL-C) - Full Analysis Set

    Baseline was defined as value obtained on Day 1 (first day of treatment). High-density lipoprotein cholesterol (HDL-C) was measured in millimoles per liter (mmol/L) and obtained through local laboratories.

    Time frame: Baseline to Week 16

  5. Mean Change From Baseline at Week 16 (95% Confidence Interval) in Fasting Triglycerides (TG) - Full Analysis Set

    Baseline was defined as value obtained on Day 1 (first day of treatment). Triglycerides (TG) were measured in millimoles per liter (mmol/L)and values obtained through local laboratories.

    Time frame: Baseline to Week 16

  6. Mean Change From Baseline at Week 16 (95% Confidence Interval) in C-Reactive Protein (CRP) - Full Analysis Set

    Baseline was defined as value obtained on Day 1 (first day of treatment). C-Reactive Protein (CRP) was measured in milligrams/liter (mg/L) and values were obtained through a central laboratory; normal was less than 5.0 mg/L.

    Time frame: Baseline to Week 16

  7. Mean Change From Baseline at Week 16 (95% Confidence Interval) in Plasminogen Activator Inhibitor-1 (PAI-1) - Full Analysis Set

    Baseline was defined as value obtained on Day 1 (first day of treatment). PAI-1 (activity) was measured in units/milliliter (U/mL)and values obtained through a central laboratory; normal was less than 25.00 U/mL.

    Time frame: Baseline to Week 16

  8. Mean Change From Baseline at Week 16 (95% Confidence Interval) in Adiponectin - Full Analysis Set

    Baseline was defined as value obtained on Day 1 (first day of treatment). Adiponectin was measured in milligrams/liter (mg/L) and values obtained through a central laboratory; normal range was 1.20 to 20.00 mg/L.

    Time frame: Baseline to Week 16

Other outcomes

  1. Number of Participants With Episodes of Lactic Acidosis or Hypoglycemia From Day 1 to Week 16 - Safety Population

    Day 1 was first day of treatment. Lactic acidosis defined as elevated blood lactate levels (\>5 mmol/L), decreased blood pH, electrolyte disturbances with an increased anion gap, and increased lactate/pyruvate ratio. Hypoglycemia (low levels of blood glucose) was reported as an adverse event. Safety population included participants who had enrolled in the study and took at least 1 dose of glucophage extended release (glucophage XR). If a subject experienced more than one adverse event, the subject was counted once at the highest severity.

    Time frame: Day 1 to Week 16

  2. Number of Participants With Clinically Significant Changes From Baseline at Week 16 in the Hematology Laboratory Test Profile - Safety Population

    Hematology profile = hematocrit, hemoglobin, red blood cell count (RBC), white blood cell count(WBC), lymphocytes, monocytes, basophils, eosinophils, neutrophils, platelet count. Baseline: value obtained at screening or last value obtained before treatment. LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Hemoglobin (g/dL): \>3 g/dL decrease from preRX; hematocrit (%): \<0.75\*preRX; RBC (\*10\^6 c/uL): \<0.75\*preRX; platelet count (\*10\^9 c/uL): \<0.67\*LLN or \>1.5\*ULN, of if preRX\<LLN, use 0.5\*preRX and \<100,000/mm\^3; WBC (\*10\^3 c/uL): \<0.75\*LLN or \>1.25\*ULN, or if preRX \<LLN, use \<0.8\*preRX or \>ULN, or if preRX\>ULN, use \>1.2\*preRX or \<LLN; neutrophils+bands (\*10\^3 c/uL): if value \<1.0\*10\^3 c/uL; eosinophils (\*10\^3 c/uL): if value \>0.750\*10\^3 c/uL; basophils (\*10\^3 c/uL): if value \>400/mm\^3; monocytes (\*10\^3 c/uL): if value \>2000/mm\^3; lymphocytes (\*10\^3 c/uL): if value \<0.750\*10\^3 c/uL or if value \>7.50\*10\^3 c/uL.

    Time frame: Baseline to Week 16

  3. Number of Participants Who Had Abnormal Increase From Baseline at Week 16 in Kidney or Liver Function Serum Chemistry Values - Safety Population

    Baseline defined as value obtained either in screening visit or last value obtained before glucophage XR treatment given on Day 1. Serum chemistries evaluating kidney or liver function: blood urea nitrogen(BUN), serum creatinine (SCr), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), total bilirubin (BR), uric acid (UA). Abnormal increase in kidney and liver function tests defined as 1.25 - less than, equal to (\<=)2.6 times (x) upper limit of normal (ULN)in ALT, AST, total BR, UA; abnormal increase defined as 1.25 to \<= 5.1 x ULN in BUN. Safety population included participants who enrolled in the study and took at least 1 dose of Glucophage XR.

    Time frame: Baseline to Week 16

  4. Number of Participants With Clinically Significant Changes From Baseline at Week 16 in Urinalysis - Safety Population

    Urinalysis included pH and specific gravity. Baseline defined as values obtained at screening visit. Clinically significant: outside the reference range (low/high)and judged to be significant by the investigator: Specific gravity 1.003 - 1.035; ph 5 - 8. Safety population included participants who enrolled in the study and took at least 1 dose of Glucophage XR.

    Time frame: Baseline to Week 16

  5. Mean Change From Baseline at Week at Week 16 in ECG Parameter Heart Rate (HR) - Safety Population

    Baseline was defined as ECG obtained at the screening visit. ECG was 12-lead. Heart rate (HR) was measured in beats per minute (beats/min). Safety population included participants who enrolled in the study and took at least 1 dose of Glucophage XR.

    Time frame: Baseline to Week 16

  6. Mean Change From Baseline at Week 16 in Diastolic and Systolic Blood Pressure - Safety Population

    Baseline was defined as the value obtained at screening or value obtained on Day 1 before treatment. Diastolic and systolic blood pressure was measured in millimeters of mercury (mm Hg). Safety population included participants who enrolled in the study and took at least 1 dose of Glucophage XR.

    Time frame: Baseline to Week 16

  7. Number of Participants Who Had a Normal Electrocardiogram (ECG) at Baseline and an ECG at Week 16 (or Termination Visit) Which Was Considered to be Abnormal With Clinical Significance - Safety Population

    Baseline was defined as ECG obtained at the screening visit. A judgment of clinical significance was at the discretion of the investigator. Safety population included participants who enrolled in the study and took at least 1 dose of Glucophage XR.

    Time frame: Baseline to Week 16

07

Results

Posted Aug 20, 2013

Participant flow

Started November 2009, Completed March 2011 at Peking University People's Hospital. Participants diagnosed with Type 2 diabetes mellitus 6 months prior to enrollment; were oral antidiabetic agent naive (either having received no antidiabetic agents or received agents 14 days or less, or received none within a month of enrollment in the study.

Participant flow — Overall Study
MilestoneGlucophage XR in Normal Weight ParticipantsGlucophage XR in Overweight ParticipantsGlucophage XR in Obese Participants
Started125122124
Completed109107109
Not completed161515
Withdrew: Adverse event547
Withdrew: Withdrawal by subject455
Withdrew: Lost to follow-up332
Withdrew: Protocol violation030
Withdrew: Lack of efficacy200
Withdrew: Immigration100
Withdrew: Other101

Outcome measures

PrimaryMean Change From Baseline at Week 16 (95% Confidence Interval) in Glycosated Hemoglobin A1c (HbA1c) (Last Observation Carried Forward) - Full Analysis Set (FAS)

Baseline for HbA1c is defined as that value obtained at screening visit. HbA1c was measured as a percent (%) of hemoglobin; normal range was 4.7 to 6.4% and values were obtained through a central laboratory. The Last Observation Carried Forward (LOCF) data set includes data recorded at a given visit or, if no observation is recorded at that visit, data carried forward from the previous visit.

Time frame:
Baseline to Week 16
Reported as:
Mean · percentage of hemoglobin
Mean Change From Baseline at Week 16 (95% Confidence Interval) in Glycosated Hemoglobin A1c (HbA1c) (Last Observation Carried Forward) - Full Analysis Set (FAS)
percentage of hemoglobinGlucophage XR in Normal Weight ParticipantsGlucophage XR in Overweight ParticipantsGlucophage XR in Obese Participants
Mean Change From Baseline at Week 16 (95% Confidence Interval) in Glycosated Hemoglobin A1c (HbA1c) (Last Observation Carried Forward) - Full Analysis Set (FAS)-1.95 ± 0.922-1.79 ± 0.941-1.68 ± 0.854
Statistical analysis
  • Glucophage XR in Normal Weight Participants vs Glucophage XR in Overweight Participants vs Glucophage XR in Obese Participants · ANCOVA · p = 0.0806 (Interpretation based on 2-sided 5% significance level.)Change from baseline in HbA1c at Week 16 was dependent variable, BMI was fixed main effect, baseline HbA1c was covariate.
  • Glucophage XR in Normal Weight Participants vs Glucophage XR in Overweight Participants · t-test, 2 sided · p = 0.1984 (Interpretation of two-by-two comparison based on 2-sided 5% significance level without correction for multiplicity.)
  • Glucophage XR in Normal Weight Participants vs Glucophage XR in Obese Participants · t-test, 2 sided · p = 0.0232 (Interpretation of two-by-two comparison based on 2-sided 5% significance level without correction for multiplicity.)
  • Glucophage XR in Overweight Participants vs Glucophage XR in Obese Participants · t-test, 2 sided · p = 0.3589 (Interpretation of two-by-two comparison based on 2-sided 5% significance level without correction for multiplicity.)
SecondaryMean Change From Baseline at Week 16 (95% Confidence Interval) of Fasting Plasma Glucose (FPG) - Full Analysis Set

Baseline was defined as the value obtained at the screening visit. FPG was measured in millimoles/Liter (mmol/L) and obtained through local laboratories.

Time frame:
Baseline to Week 16
Reported as:
Mean · mmol/L
Mean Change From Baseline at Week 16 (95% Confidence Interval) of Fasting Plasma Glucose (FPG) - Full Analysis Set
mmol/LGlucophage XR in Normal Weight ParticipantsGlucophage XR in Overweight ParticipantsGlucophage XR in Obese Participants
Mean Change From Baseline at Week 16 (95% Confidence Interval) of Fasting Plasma Glucose (FPG) - Full Analysis Set-1.979 ± 1.7877-2.171 ± 2.1222-2.141 ± 2.0287
Statistical analysis
  • Glucophage XR in Normal Weight Participants vs Glucophage XR in Overweight Participants vs Glucophage XR in Obese Participants · ANCOVA · p = 0.4614 (Interpretation based on 2-sided 5% significance level.)Change from baseline in FPG at Week 16 was dependent variable, BMI was fixed main effect, baseline FPG was covariate.
  • Glucophage XR in Normal Weight Participants vs Glucophage XR in Overweight Participants · t-test, 2 sided · p = 0.4696 (Interpretation of two-by-two comparison based on 2-sided 5% significance level without correction for multiplicity.)
  • Glucophage XR in Normal Weight Participants vs Glucophage XR in Obese Participants · t-test, 2 sided · p = 0.5305 (Interpretation of two-by-two comparison based on 2-sided 5% significance level without correction for multiplicity.)
  • Glucophage XR in Overweight Participants vs Glucophage XR in Obese Participants · t-test, 2 sided · p = 0.9145 (Interpretation of two-by-two comparison based on 2-sided 5% significance level without correction for multiplicity.)
SecondaryMean Change From Baseline at Week 16 (95% Confidence Interval) in Fasting Total Cholesterol (TC) - Full Analysis Set

For fasting total cholesterol (TC), baseline is defined as Day 1 (first day of treatment). Total cholesterol was measured in millimoles per liter (mmol/L) and obtained through local laboratories.

Time frame:
Baseline to Week 16
Reported as:
Mean · mmol/L
Mean Change From Baseline at Week 16 (95% Confidence Interval) in Fasting Total Cholesterol (TC) - Full Analysis Set
mmol/LGlucophage XR in Normal Weight ParticipantsGlucophage XR in Overweight ParticipantsGlucophage XR in Obese Participants
Mean Change From Baseline at Week 16 (95% Confidence Interval) in Fasting Total Cholesterol (TC) - Full Analysis Set-0.388 ± 0.9164-0.048 ± 0.9560-0.144 ± 0.8188
Statistical analysis
  • Glucophage XR in Normal Weight Participants vs Glucophage XR in Overweight Participants vs Glucophage XR in Obese Participants · ANCOVA · p = 0.0305 (Interpretation based on 2-sided 5% significance level.)Change from baseline in TC at Week 16 was dependent variable, BMI was fixed main effect, baseline TC was covariate.
  • Glucophage XR in Normal Weight Participants vs Glucophage XR in Overweight Participants · t-test, 2 sided · p = 0.0080 (Interpretation of two-by-two comparison based on 2-sided 5% significance level without correction for multiplicity. For lipids, no comparison between overweight and obese was performed.)
  • Glucophage XR in Normal Weight Participants vs Glucophage XR in Obese Participants · t-test, 2 sided · p = 0.0422 (Interpretation of two-by-two comparison based on 2-sided 5% significance level without correction for multiplicity. For lipids, no comparison between overweight and obese was performed.)
SecondaryMean Change From Baseline at Week 16 (95% Confidence Interval) in Fasting Low-density Lipoprotein Cholesterol (LDL-C) - Full Analysis Set

Baseline was defined as values obtained on Day 1. Low-density lipoprotein cholesterol (LDL-C) was measured in millimoles per liter (mmol/L) and obtained through local laboratories.

Time frame:
Baseline to Week 16
Reported as:
Mean · mmol/L
Mean Change From Baseline at Week 16 (95% Confidence Interval) in Fasting Low-density Lipoprotein Cholesterol (LDL-C) - Full Analysis Set
mmol/LGlucophage XR in Normal Weight ParticipantsGlucophage XR in Overweight ParticipantsGlucophage XR in Obese Participants
Mean Change From Baseline at Week 16 (95% Confidence Interval) in Fasting Low-density Lipoprotein Cholesterol (LDL-C) - Full Analysis Set-0.306 ± 0.5746-0.143 ± 0.6605-0.181 ± 0.6258
Statistical analysis
  • Glucophage XR in Normal Weight Participants vs Glucophage XR in Overweight Participants vs Glucophage XR in Obese Participants · ANCOVA · p = 0.4508 (Interpretation based on 2-sided 5% significance level.)Change from baseline in LDL-C at Week 16 was dependent variable, BMI was fixed main effect, baseline LDL-C was covariate.
  • Glucophage XR in Normal Weight Participants vs Glucophage XR in Overweight Participants · t-test, 2 sided · p = 0.0526 (Interpretation of two-by-two comparison based on 2-sided 5% significance level without correction for multiplicity. For lipids, no comparison between overweight and obese was performed.)
  • Glucophage XR in Normal Weight Participants vs Glucophage XR in Obese Participants · t-test, 2 sided · p = 0.1295 (Interpretation of two-by-two comparison based on 2-sided 5% significance level without correction for multiplicity. For lipids, no comparison between overweight and obese was performed.)
SecondaryMean Change From Baseline at Week 16 (95% Confidence Interval) in Fasting High-density Lipoprotein Cholesterol (HDL-C) - Full Analysis Set

Baseline was defined as value obtained on Day 1 (first day of treatment). High-density lipoprotein cholesterol (HDL-C) was measured in millimoles per liter (mmol/L) and obtained through local laboratories.

Time frame:
Baseline to Week 16
Reported as:
Mean · mmol/L
Mean Change From Baseline at Week 16 (95% Confidence Interval) in Fasting High-density Lipoprotein Cholesterol (HDL-C) - Full Analysis Set
mmol/LGlucophage XR in Normal Weight ParticipantsGlucophage XR in Overweight ParticipantsGlucophage XR in Obese Participants
Mean Change From Baseline at Week 16 (95% Confidence Interval) in Fasting High-density Lipoprotein Cholesterol (HDL-C) - Full Analysis Set0.056 ± 0.20160.024 ± 0.34280.032 ± 0.2042
Statistical analysis
  • Glucophage XR in Normal Weight Participants vs Glucophage XR in Overweight Participants vs Glucophage XR in Obese Participants · ANCOVA · p = 0.1431 (Interpretation based on 2-sided 5% significance level.)Change from baseline in HDL-C at Week 16 was dependent variable, BMI was fixed main effect, baseline HDL-C was covariate.
  • Glucophage XR in Normal Weight Participants vs Glucophage XR in Overweight Participants · t-test, 2 sided · p = 0.4066 (Interpretation of two-by-two comparison based on 2-sided 5% significance level without correction for multiplicity. For lipids, no comparison between overweight and obese was performed.)
  • Glucophage XR in Normal Weight Participants vs Glucophage XR in Obese Participants · t-test, 2 sided · p = 0.4071 (Interpretation of two-by-two comparison based on 2-sided 5% significance level without correction for multiplicity. For lipids, no comparison between overweight and obese was performed.)
SecondaryMean Change From Baseline at Week 16 (95% Confidence Interval) in Fasting Triglycerides (TG) - Full Analysis Set

Baseline was defined as value obtained on Day 1 (first day of treatment). Triglycerides (TG) were measured in millimoles per liter (mmol/L)and values obtained through local laboratories.

Time frame:
Baseline to Week 16
Reported as:
Mean · mmol/L
Mean Change From Baseline at Week 16 (95% Confidence Interval) in Fasting Triglycerides (TG) - Full Analysis Set
mmol/LGlucophage XR in Normal Weight ParticipantsGlucophage XR in Overweight ParticipantsGlucophage XR in Obese Participants
Mean Change From Baseline at Week 16 (95% Confidence Interval) in Fasting Triglycerides (TG) - Full Analysis Set-0.172 ± 2.06780.262 ± 3.3195-0.041 ± 2.2018
Statistical analysis
  • Glucophage XR in Normal Weight Participants vs Glucophage XR in Overweight Participants vs Glucophage XR in Obese Participants · ANCOVA · p = 0.0210 (Interpretation based on 2-sided 5% significance level.)Change from baseline in TG at Week 16 was dependent variable, BMI was fixed main effect, baseline TG was covariate.
  • Glucophage XR in Normal Weight Participants vs Glucophage XR in Overweight Participants · t-test, 2 sided · p = 0.2507 (Interpretation of two-by-two comparison based on 2-sided 5% significance level without correction for multiplicity. For lipids, no comparison between overweight and obese was performed.)
  • Glucophage XR in Normal Weight Participants vs Glucophage XR in Obese Participants · t-test, 2 sided · p = 0.6546 (Interpretation of two-by-two comparison based on 2-sided 5% significance level without correction for multiplicity. For lipids, no comparison between overweight and obese was performed.)
SecondaryMean Change From Baseline at Week 16 (95% Confidence Interval) in C-Reactive Protein (CRP) - Full Analysis Set

Baseline was defined as value obtained on Day 1 (first day of treatment). C-Reactive Protein (CRP) was measured in milligrams/liter (mg/L) and values were obtained through a central laboratory; normal was less than 5.0 mg/L.

Time frame:
Baseline to Week 16
Reported as:
Mean · mg/L
Mean Change From Baseline at Week 16 (95% Confidence Interval) in C-Reactive Protein (CRP) - Full Analysis Set
mg/LGlucophage XR in Normal Weight ParticipantsGlucophage XR in Overweight ParticipantsGlucophage XR in Obese Participants
Mean Change From Baseline at Week 16 (95% Confidence Interval) in C-Reactive Protein (CRP) - Full Analysis Set-0.589 ± 1.09143.144 ± 16.40191.633 ± 8.0706
SecondaryMean Change From Baseline at Week 16 (95% Confidence Interval) in Plasminogen Activator Inhibitor-1 (PAI-1) - Full Analysis Set

Baseline was defined as value obtained on Day 1 (first day of treatment). PAI-1 (activity) was measured in units/milliliter (U/mL)and values obtained through a central laboratory; normal was less than 25.00 U/mL.

Time frame:
Baseline to Week 16
Reported as:
Mean · U/mL
Mean Change From Baseline at Week 16 (95% Confidence Interval) in Plasminogen Activator Inhibitor-1 (PAI-1) - Full Analysis Set
U/mLGlucophage XR in Normal Weight ParticipantsGlucophage XR in Overweight ParticipantsGlucophage XR in Obese Participants
Mean Change From Baseline at Week 16 (95% Confidence Interval) in Plasminogen Activator Inhibitor-1 (PAI-1) - Full Analysis Set0.465 ± 8.52331.177 ± 8.9405-1.792 ± 7.9231
SecondaryMean Change From Baseline at Week 16 (95% Confidence Interval) in Adiponectin - Full Analysis Set

Baseline was defined as value obtained on Day 1 (first day of treatment). Adiponectin was measured in milligrams/liter (mg/L) and values obtained through a central laboratory; normal range was 1.20 to 20.00 mg/L.

Time frame:
Baseline to Week 16
Reported as:
Mean · mg/L
Mean Change From Baseline at Week 16 (95% Confidence Interval) in Adiponectin - Full Analysis Set
mg/LGlucophage XR in Normal Weight ParticipantsGlucophage XR in Overweight ParticipantsGlucophage XR in Obese Participants
Mean Change From Baseline at Week 16 (95% Confidence Interval) in Adiponectin - Full Analysis Set1.742 ± 8.65031.102 ± 2.21160.050 ± 3.5516
Other pre-specifiedNumber of Participants With Episodes of Lactic Acidosis or Hypoglycemia From Day 1 to Week 16 - Safety Population

Day 1 was first day of treatment. Lactic acidosis defined as elevated blood lactate levels (\>5 mmol/L), decreased blood pH, electrolyte disturbances with an increased anion gap, and increased lactate/pyruvate ratio. Hypoglycemia (low levels of blood glucose) was reported as an adverse event. Safety population included participants who had enrolled in the study and took at least 1 dose of glucophage extended release (glucophage XR). If a subject experienced more than one adverse event, the subject was counted once at the highest severity.

Time frame:
Day 1 to Week 16
Reported as:
Number · participants
Number of Participants With Episodes of Lactic Acidosis or Hypoglycemia From Day 1 to Week 16 - Safety Population
participantsGlucophage XR in Normal Weight ParticipantsGlucophage XR in Overweight ParticipantsGlucophage XR in Obese Participants
Lactic Acidosis000
Hypoglycemia100
Other pre-specifiedNumber of Participants With Clinically Significant Changes From Baseline at Week 16 in the Hematology Laboratory Test Profile - Safety Population

Hematology profile = hematocrit, hemoglobin, red blood cell count (RBC), white blood cell count(WBC), lymphocytes, monocytes, basophils, eosinophils, neutrophils, platelet count. Baseline: value obtained at screening or last value obtained before treatment. LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Hemoglobin (g/dL): \>3 g/dL decrease from preRX; hematocrit (%): \<0.75\*preRX; RBC (\*10\^6 c/uL): \<0.75\*preRX; platelet count (\*10\^9 c/uL): \<0.67\*LLN or \>1.5\*ULN, of if preRX\<LLN, use 0.5\*preRX and \<100,000/mm\^3; WBC (\*10\^3 c/uL): \<0.75\*LLN or \>1.25\*ULN, or if preRX \<LLN, use \<0.8\*preRX or \>ULN, or if preRX\>ULN, use \>1.2\*preRX or \<LLN; neutrophils+bands (\*10\^3 c/uL): if value \<1.0\*10\^3 c/uL; eosinophils (\*10\^3 c/uL): if value \>0.750\*10\^3 c/uL; basophils (\*10\^3 c/uL): if value \>400/mm\^3; monocytes (\*10\^3 c/uL): if value \>2000/mm\^3; lymphocytes (\*10\^3 c/uL): if value \<0.750\*10\^3 c/uL or if value \>7.50\*10\^3 c/uL.

Time frame:
Baseline to Week 16
Reported as:
Number · participants
Number of Participants With Clinically Significant Changes From Baseline at Week 16 in the Hematology Laboratory Test Profile - Safety Population
participantsGlucophage XR in Normal Weight ParticipantsGlucophage XR in Overweight ParticipantsGlucophage XR in Obese Participants
Number of Participants With Clinically Significant Changes From Baseline at Week 16 in the Hematology Laboratory Test Profile - Safety Population000
Other pre-specifiedNumber of Participants Who Had Abnormal Increase From Baseline at Week 16 in Kidney or Liver Function Serum Chemistry Values - Safety Population

Baseline defined as value obtained either in screening visit or last value obtained before glucophage XR treatment given on Day 1. Serum chemistries evaluating kidney or liver function: blood urea nitrogen(BUN), serum creatinine (SCr), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), total bilirubin (BR), uric acid (UA). Abnormal increase in kidney and liver function tests defined as 1.25 - less than, equal to (\<=)2.6 times (x) upper limit of normal (ULN)in ALT, AST, total BR, UA; abnormal increase defined as 1.25 to \<= 5.1 x ULN in BUN. Safety population included participants who enrolled in the study and took at least 1 dose of Glucophage XR.

Time frame:
Baseline to Week 16
Reported as:
Number · participants
Number of Participants Who Had Abnormal Increase From Baseline at Week 16 in Kidney or Liver Function Serum Chemistry Values - Safety Population
participantsGlucophage XR in Normal Weight ParticipantsGlucophage XR in Overweight ParticipantsGlucophage XR in Obese Participants
Number with Week 16 ALT 1.25 to <= 2.6xULN2119
Number with Week 16 ALT > 2.6 x ULN000
Number with Week 16 AST 1.25 to <= 2.6xULN054
Number with Week 16 AST > 2.6 x ULN000
Number with Week 16 Total BR 1.25 to <=2.6xULN321
Number with Week 16 Total BR > 2.6 x ULN000
Number with Week 16 BUN1.25 to <=5.1xULN010
Number with Week 16 BUN > 5.1 x ULN000
Number with Week 16 UA 1.25 to <=2.6xULN357
Number with Week 16 UA > 2.6 x ULN000
Number with Week 16 SCr 1.25 to <=2.6xULN000
Number with Week 16 SCr > 1.25 x ULN000
Other pre-specifiedNumber of Participants With Clinically Significant Changes From Baseline at Week 16 in Urinalysis - Safety Population

Urinalysis included pH and specific gravity. Baseline defined as values obtained at screening visit. Clinically significant: outside the reference range (low/high)and judged to be significant by the investigator: Specific gravity 1.003 - 1.035; ph 5 - 8. Safety population included participants who enrolled in the study and took at least 1 dose of Glucophage XR.

Time frame:
Baseline to Week 16
Reported as:
Number · participants
Number of Participants With Clinically Significant Changes From Baseline at Week 16 in Urinalysis - Safety Population
participantsGlucophage XR in Normal Weight ParticipantsGlucophage XR in Overweight ParticipantsGlucophage XR in Obese Participants
Number of Participants With Clinically Significant Changes From Baseline at Week 16 in Urinalysis - Safety Population000
Other pre-specifiedMean Change From Baseline at Week at Week 16 in ECG Parameter Heart Rate (HR) - Safety Population

Baseline was defined as ECG obtained at the screening visit. ECG was 12-lead. Heart rate (HR) was measured in beats per minute (beats/min). Safety population included participants who enrolled in the study and took at least 1 dose of Glucophage XR.

Time frame:
Baseline to Week 16
Reported as:
Mean · beats/min
Mean Change From Baseline at Week at Week 16 in ECG Parameter Heart Rate (HR) - Safety Population
beats/minGlucophage XR in Normal Weight ParticipantsGlucophage XR in Overweight ParticipantsGlucophage XR in Obese Participants
Mean Change From Baseline at Week at Week 16 in ECG Parameter Heart Rate (HR) - Safety Population0.4 ± 8.911.2 ± 9.561.1 ± 12.36
Other pre-specifiedMean Change From Baseline at Week 16 in Diastolic and Systolic Blood Pressure - Safety Population

Baseline was defined as the value obtained at screening or value obtained on Day 1 before treatment. Diastolic and systolic blood pressure was measured in millimeters of mercury (mm Hg). Safety population included participants who enrolled in the study and took at least 1 dose of Glucophage XR.

Time frame:
Baseline to Week 16
Reported as:
Mean · mm Hg
Mean Change From Baseline at Week 16 in Diastolic and Systolic Blood Pressure - Safety Population
mm HgGlucophage XR in Normal Weight ParticipantsGlucophage XR in Overweight ParticipantsGlucophage XR in Obese Participants
Week 16 change in diastolic blood pressure-2.2 ± 8.63-4.1 ± 9.31-1.4 ± 9.37
Week 16 change in systolic blood pressure-4.6 ± 14.21-5.5 ± 12.14-1.7 ± 14.55
Other pre-specifiedNumber of Participants Who Had a Normal Electrocardiogram (ECG) at Baseline and an ECG at Week 16 (or Termination Visit) Which Was Considered to be Abnormal With Clinical Significance - Safety Population

Baseline was defined as ECG obtained at the screening visit. A judgment of clinical significance was at the discretion of the investigator. Safety population included participants who enrolled in the study and took at least 1 dose of Glucophage XR.

Time frame:
Baseline to Week 16
Reported as:
Number · participants
Number of Participants Who Had a Normal Electrocardiogram (ECG) at Baseline and an ECG at Week 16 (or Termination Visit) Which Was Considered to be Abnormal With Clinical Significance - Safety Population
participantsGlucophage XR in Normal Weight ParticipantsGlucophage XR in Overweight ParticipantsGlucophage XR in Obese Participants
Number of Participants Who Had a Normal Electrocardiogram (ECG) at Baseline and an ECG at Week 16 (or Termination Visit) Which Was Considered to be Abnormal With Clinical Significance - Safety Population013

Adverse events

Collected over 16 Weeks. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Glucophage XR in Normal Weight Participants—1/125 (0.8%)43/125 (34.4%)
Glucophage XR in Overweight Participants—0/122 (0%)47/122 (38.5%)
Glucophage XR in Obese Participants—1/124 (0.8%)46/124 (37.1%)
Most frequent serious events
Most frequent serious events
EventGlucophage XR in Normal Weight ParticipantsGlucophage XR in Overweight ParticipantsGlucophage XR in Obese Participants
HypertensionBlood and lymphatic system disorders0/1250/1221/124
Right upper lung cancerRespiratory, thoracic and mediastinal disorders1/1250/1220/124
Most frequent other events
Showing 10 of 77
Most frequent other events
EventGlucophage XR in Normal Weight ParticipantsGlucophage XR in Overweight ParticipantsGlucophage XR in Obese Participants
DiarrheaGastrointestinal disorders18/12512/1224/124
Abdominal discomfortGastrointestinal disorders2/12513/1222/124
Abdominal distensionGastrointestinal disorders6/1259/1222/124
HyperuricemiaMetabolism and nutrition disorders0/1252/1226/124
DizzinessNervous system disorders6/1254/1224/124
palpitationsCardiac disorders6/1254/1221/124
NauseaGastrointestinal disorders2/1255/1224/124
ConstipationGastrointestinal disorders4/1251/1222/124
Abdominal pain upperGastrointestinal disorders3/1253/1222/124
FatigueGeneral disorders0/1253/1221/124

Baseline characteristics

Baseline population consisted of: all participants enrolled into one of three body weight arms, normal, overweight or obese, based on body mass index at screening; and who were assigned to treatment with Glucophage XR. This population was used for analysis of demographics.

Age Continuous
Age Continuous(years)Glucophage XR in Normal Weight ParticipantsGlucophage XR in Overweight ParticipantsGlucophage XR in Obese ParticipantsTotal
Median53.0 ± 10.3251.0 ± 9.2152.5 ± 10.9752.0 ± 10.17
Sex: Female, Male
Sex: Female, Male(Participants)Glucophage XR in Normal Weight ParticipantsGlucophage XR in Overweight ParticipantsGlucophage XR in Obese ParticipantsTotal
Female644552161
Male617772210
Region of Enrollment
Region of Enrollment(participants)Glucophage XR in Normal Weight ParticipantsGlucophage XR in Overweight ParticipantsGlucophage XR in Obese ParticipantsTotal
China125122124371
08

Study locations

14 sites
  • Local Institution
    Beijing, Beijing 100028, China
  • Local Institution
    Beijing, Beijing 100034, China
  • Local Institution
    Beijing, Beijing 100044, China
  • Local Institution
    Beijing, Beijing 100088, China
  • Local Institution
    Beijing, Beijing 100730, China
  • Local Institution
    Beijing, Beijing 101100, China
  • Local Institution
    Beijing, Beijing 200016, China
  • Local Institution
    Guangdong Province, Guangdong 510180, China
  • Local Institution
    Guangdong Province, Guangdong 528000, China
  • Local Institution
    Guangdong, Guangdong 510180, China
  • Local Institution
    Shanghai, Shanghai 200003, China
  • Local Institution
    Shanghai, Shanghai 200092, China
  • Local Institution
    Shanghai, Shanghai 201100, China
  • Local Institution
    Shanghai, Shanghai 201200, China
09

References and documents

Publications

  • Ji L, Li H, Guo X, Li Y, Hu R, Zhu Z. Impact of baseline BMI on glycemic control and weight change with metformin monotherapy in Chinese type 2 diabetes patients: phase IV open-label trial. PLoS One. 2013;8(2):e57222. doi: 10.1371/journal.pone.0057222. Epub 2013 Feb 28. PubMed 23468941 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2009, a primary completion of Mar 2011 and a completion of Mar 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2008
First posted
Oct 23, 2008
Start
Nov 2009
Primary completionActual
Mar 2011
CompletionActual
Mar 2011
Results first posted
Aug 20, 2013
Last update
Aug 23, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00778622
Responsible party
Sponsor
First posted
Oct 23, 2008
Start date
Nov 2009
Primary completion
Mar 2011
Completion
Mar 2011
Results posted
Aug 20, 2013
Last update
Aug 23, 2013

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion